Dr. Kevin Douglas Becker, MD

Dr. Becker practices at Maimonides Cancer Center in Brooklyn, New York.

Dr. Becker's NPI, 1023275633, was assigned on May 21, 2008. Dr. Becker graduated from Vagelos College of Physicians and Surgeons in 2004. Dr. Becker's New York license number on file is 240282.

Dr. Becker's primary practice is Maimonides Cancer Center, at 6300 8th Ave, Brooklyn, NY 11220 in Kings County. The practice phone is (718) 283-8773.

Dr. Becker's primary practice is Maimonides Cancer Center in Brooklyn, New York. Dr. Becker is also affiliated with Maimonides Medical Center. The medical group on file is Maimonides Medical Center. Dmand AI also links Dr. Becker to 4 more hospitals, 5 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Becker practices, 8 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Becker's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Becker is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Becker's licenses on file in 2 states: New York and South Carolina.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, fluid and electrolyte imbalances, lung cancer and prostate cancer among the conditions Dr. Becker treats.

CMS data shows 291 Medicare services from Dr. Becker across 5 procedure codes in 2024, for 133 Medicare patients. Medicare paid $21,898 for them.

CMS counts 133 Medicare patients who saw Dr. Becker in 2024. The largest group is 75 to 84, with 54 patients. 75% of them have cancer, and 75% have high blood pressure. 32% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Becker's median patient age at 72, with 25% women.

In 2024, Dr. Becker wrote 625 Medicare Part D claims for 76 patients. 60% of them were for generic drugs. CMS names the drug for 519 of them, across 10 drugs with 11 or more claims each, at $3,293,936 in total drug cost. In 2023, CMS named 649 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Becker for performance year 2024, reported as part of a group. Dr. Becker accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Becker as offering telehealth.

Dmand AI links 9 papers to Dr. Becker, published from 2015 to 2023. 2021 was the busiest year, with 2. The most frequent topics are Lung Neoplasms, Drug Resistance, Neoplasm and ErbB Receptors. Dr. Becker's most frequent co-authors are Kevin Becker, MD, PhD, Daniel Jacob Becker, MD and Bernadine R. Donahue, MD.

Dmand AI links Dr. Becker to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Adenocarcinoma, Bronchiolo-Alveolar, Neoplasm Metastasis and Adenocarcinoma of Lung. Open Payments lists research payments to Dr. Becker that name 1 trial.

CMS Open Payments shows 315 general payments to Dr. Becker from 40 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Bristol-Myers Squibb Company paid the most, $24,669. It also lists 1 research payment totaling $320 in 2023, naming 1 clinical trial.

Dr. Becker graduated from Vagelos College of Physicians and Surgeons in 2004.

Dr. Becker is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.